Literature DB >> 22361863

High TrkB expression levels are associated with poor prognosis and EMT induction in colorectal cancer cells.

Hiroyuki Fujikawa1, Koji Tanaka, Yuji Toiyama, Susumu Saigusa, Yasuhiro Inoue, Keiichi Uchida, Masato Kusunoki.   

Abstract

BACKGROUND: The neurotrophic receptor tropomyosin related kinase (TrkB) is associated with tumor progression in neuroblastoma and certain human malignancies. Recent reports indicate TrkB may participate in the epithelial-mesenchymal transition (EMT). This study investigates whether TrkB expression is associated with the clinical outcome of colorectal cancer (CRC) patients and whether TrkB induces EMT in CRC cells.
METHODS: TrkB and E-cadherin expression in surgical tissue samples and clinicopathological data from 102 CRC patients were analyzed by real-time polymerase chain reaction and immunohistochemistry. The biological role of TrkB in CRC was analyzed using RNA interference against TrkB in the CRC cell line SW480 to assess tumor progression and the correlation between TrkB and E-cadherin expression.
RESULTS: Patients with high TrkB mRNA expression in clinical samples had a significantly poorer prognosis relative to those with low TrkB levels (p = 0.03). TrkB was inversely correlated with E-cadherin at both the mRNA and protein levels. In vitro, cell proliferation (p = 0.02), migration (p < 0.001), and invasion (p < 0.001) were significantly inhibited by TrkB knockdown while the anoikis rate increased in TrkB siRNA-transfected cells compared to control siRNA. Interestingly, E-cadherin expression in TrkB siRNA-transfected cells was higher than in control cells and vimentin was lower conversely.
CONCLUSIONS: High TrkB expression is associated with poor prognosis in CRC patients and enhanced malignant potential in terms of proliferation, migration, invasion, and anoikis inhibition in CRC cells. These results indicate TrkB could induce EMT and play an important role in CRC progression to metastasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22361863     DOI: 10.1007/s00535-012-0532-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  30 in total

Review 1.  The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it.

Authors:  Elizabeth D Hay
Journal:  Dev Dyn       Date:  2005-07       Impact factor: 3.780

2.  Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.

Authors:  Anthony D Yang; Fan Fan; E Ramsay Camp; George van Buren; Wenbiao Liu; Ray Somcio; Michael J Gray; Haiyun Cheng; Paulo M Hoff; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

3.  Neurotrophic receptor, tropomyosin-related kinase B, as a chemoresistant marker in oesophageal cancer.

Authors:  K Tanaka; Y Mohri; J Nishioka; M Ohi; T Yokoe; C Miki; H Tonouchi; T Nobori; M Kusunoki
Journal:  Clin Oncol (R Coll Radiol)       Date:  2009-02-05       Impact factor: 4.126

4.  Thrombin induces expression of twist and cell motility via the hypoxia-inducible factor-1α translational pathway in colorectal cancer cells.

Authors:  Li-Hsun Chang; Chun-Han Chen; Der-Yi Huang; Hui-Chen Pai; Shiow-Lin Pan; Che-Ming Teng
Journal:  J Cell Physiol       Date:  2011-04       Impact factor: 6.384

5.  Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer.

Authors:  Xiaohui Yu; Ling Liu; Bin Cai; Yinyan He; Xiaoping Wan
Journal:  Cancer Sci       Date:  2008-01-14       Impact factor: 6.716

Review 6.  The E-cadherin adhesion molecule and colorectal cancer. A global literature approach.

Authors:  Elena Tsanou; Dimitrios Peschos; Anna Batistatou; Alexandros Charalabopoulos; Konstantinos Charalabopoulos
Journal:  Anticancer Res       Date:  2008 Nov-Dec       Impact factor: 2.480

7.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

8.  A Twist-Snail axis critical for TrkB-induced epithelial-mesenchymal transition-like transformation, anoikis resistance, and metastasis.

Authors:  Marjon A Smit; Thomas R Geiger; Ji-Ying Song; Inna Gitelman; Daniel S Peeper
Journal:  Mol Cell Biol       Date:  2009-05-04       Impact factor: 4.272

9.  TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma.

Authors:  M E Kupferman; T Jiffar; A El-Naggar; T Yilmaz; G Zhou; T Xie; L Feng; J Wang; F C Holsinger; D Yu; J N Myers
Journal:  Oncogene       Date:  2010-01-18       Impact factor: 9.867

Review 10.  The epithelial-mesenchymal transition: new insights in signaling, development, and disease.

Authors:  Jonathan M Lee; Shoukat Dedhar; Raghu Kalluri; Erik W Thompson
Journal:  J Cell Biol       Date:  2006-03-27       Impact factor: 10.539

View more
  29 in total

1.  TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung.

Authors:  Alberto Ricci; Claudia De Vitis; Alessia Noto; Luigi Fattore; Salvatore Mariotta; Emanuela Cherubini; Giuseppe Roscilli; Giuseppina Liguori; Giosuè Scognamiglio; Gaetano Rocco; Gerardo Botti; Enrico Giarnieri; Maria Rosaria Giovagnoli; Giorgio De Toma; Gennaro Ciliberto; Rita Mancini
Journal:  Cell Cycle       Date:  2013-05-02       Impact factor: 4.534

Review 2.  Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells.

Authors:  Muriel Mathonnet; Aurelie Perraud; Niki Christou; Hussein Akil; Carole Melin; Serge Battu; Marie-Odile Jauberteau; Yves Denizot
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Brain-derived neurotrophic factor/tropomyosin-related kinase B signaling pathway contributes to the aggressive behavior of lung squamous cell carcinoma.

Authors:  Keigo Ozono; Yoshihiro Ohishi; Hideya Onishi; Katsuya Nakamura; Junichi Motoshita; Masato Kato; Ryoichi Nakanishi; Masafumi Nakamura; Yoshinao Oda
Journal:  Lab Invest       Date:  2017-06-12       Impact factor: 5.662

4.  NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines.

Authors:  Jinhuai Hu; Yong Huang; Yuanhua Wu; Fengjun Liu; Dong Sun; Kexin Wang; Hui Qu
Journal:  Tumour Biol       Date:  2016-09-23

5.  Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

Authors:  Radhika Iyer; Lea Wehrmann; Rebecca L Golden; Koumudi Naraparaju; Jamie L Croucher; Suzanne P MacFarland; Peng Guan; Venkatadri Kolla; Ge Wei; Nicholas Cam; Gang Li; Zachary Hornby; Garrett M Brodeur
Journal:  Cancer Lett       Date:  2016-01-18       Impact factor: 8.679

Review 6.  Neurotrophin signaling in cancer stem cells.

Authors:  Valérie Chopin; Chann Lagadec; Robert-Alain Toillon; Xuefen Le Bourhis
Journal:  Cell Mol Life Sci       Date:  2016-02-17       Impact factor: 9.261

7.  Prognostic value of tropomyosin-related kinases A, B, and C in gastric cancer.

Authors:  A Kamiya; M Inokuchi; S Otsuki; H Sugita; K Kato; H Uetake; K Sugihara; Y Takagi; K Kojima
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

Review 8.  Tropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancer.

Authors:  Hussein Akil; Aurélie Perraud; Marie-Odile Jauberteau; Muriel Mathonnet
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

9.  Dysregulation of CUL4A and CUL4B Ubiquitin Ligases in Lung Cancer.

Authors:  Lei Jia; Fan Yan; Wenfeng Cao; Zhengming Chen; Hong Zheng; Haixin Li; Yi Pan; Navneet Narula; Xiubao Ren; Hui Li; Pengbo Zhou
Journal:  J Biol Chem       Date:  2016-12-14       Impact factor: 5.157

Review 10.  Is there still a place for conventional histopathology in the age of molecular medicine? Laurén classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis.

Authors:  Cristina Díaz Del Arco; Luis Ortega Medina; Lourdes Estrada Muñoz; Soledad García Gómez de Las Heras; Mª Jesús Fernández Aceñero
Journal:  Histol Histopathol       Date:  2021-02-10       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.